Nipah Vaccine Shows Promise; Oxford-SII Phase 2 Trial Launched in Bangladesh

An early-stage Nipah virus vaccine trial has shown promising results in safety and immune response. This advancement has led to the launch of the world's first Phase 2 clinical trial for the Oxford-developed vaccine, manufactured by India's Serum Institute, in Bangladesh, a Nipah-endemic region.

• Phase 1 Nipah vaccine trial deemed safe, triggered strong immune responses.
• Oxford University launched world's first Phase 2 trial for ChAdOx1 NipahB vaccine in Bangladesh.
• India's Serum Institute manufactured the Oxford Nipah vaccine candidate.
• Nipah virus is a WHO priority pathogen with high pandemic potential and up to 75% fatality.
• Nipah outbreaks are recurrent in South Asia, including India and Bangladesh.
• No licensed Nipah virus vaccines or treatments are currently available.

Read the full story on Quick Digest.